Shortwave therapy compared with sham treatment for nerve damage from diabetes
Tests shortwave therapy against a sham device in people with diabetic peripheral neuropathy.
Key facts
- Who runs it
- Chongqing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Shortwave Intervention for Diabetic Peripheral Neuropathy.
- Status
- Recruiting
- People taking part
- 202 people, planned
- Started
- 20 May 2026
- Expected to end
- 20 May 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Short-Wave Diathermy
- Placebo treatment group
- Record updated
- 18 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetes who have nerve damage in the legs and feet (diabetic peripheral neuropathy). It tests shortwave heat therapy against a fake (sham) treatment.
- Age
- 18 to 85 years
- Sex
- All sexes
- Disease stage
- Nerve symptoms such as numbness, tingling, burning, cold or pain that started at or after the diabetes diagnosis. Signs on nerve tests may or may not be present. People must be able to complete the TCSS nerve assessment.
- Earlier treatment
- Nerve symptoms did not improve after adequate treatment with mecobalamin and other medicines.
Main reasons for not taking part
- Nerve damage from other causes, such as lower back spine problems, vitamin B12 deficiency, alcohol or Guillain-Barré syndrome
- Bleeding disorders or cancer
- Leg amputation below the knee, skin damage or infection at the treatment site, metal implants or a pacemaker
- Severe heart, liver or kidney problems (e.g., eGFR < 15 ml/min/1.73m²), or memory and thinking problems that prevent cooperation
- Pregnancy, breastfeeding or planning a pregnancy
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- 1. Aged 18-85 years, regardless of gender, with the ability to act independently
- 2. Appearance of neuropathic symptoms or signs at the time of or after the diagnosis of diabetes, meeting the following criteria: presence of DPN symptoms (numbness, tingling, burning, cold, pain), with or without signs (abnormalities in any of ankle reflex, vibration sense, pinprick sensation, temperature sensation, or pressure sensation)
- 3. Able to complete the TCSS assessment
- 4. Understands the entire trial process, voluntarily participates in the study, and signs the informed consent form
- 5. Patients who did not respond to adequate treatment with mecobalamin and other medications
Who cannot take part
- 1. Peripheral neuropathy caused by other reasons (such as lumbar spine lesions, vitamin B12 deficiency, uncontrolled hypothyroidism, alcohol intoxication, drug neurotoxicity, Guillain-Barré syndrome, etc.)
- 2. Hemorrhagic diseases, malignant tumors
- 3. History of below-knee amputation
- 4. Skin damage, infection at the treatment site, or presence of metal implants, pacemaker
- 8. Combined severe psychiatric disorders
- 9. Other conditions assessed by the investigator that prevent completion of the trial
- 5. Combined severe heart, liver, or kidney dysfunction (e.g., eGFR < 15 ml/min/1.73m²), or cognitive impairment preventing cooperation
- 6. Pregnancy, breastfeeding, or planning pregnancy
- 7. Participation in other interventional clinical trials within the past 3 months
- 10. Poor compliance
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-center, randomized, single-blind, sham-controlled clinical trial aimed at evaluating the efficacy and safety of shortwave therapy administered for five consecutive days in the treatment of diabetic peripheral neuropathy. The study plans to enroll 202 patients, who will be randomly assigned in a 1:1 ratio to either the shortwave therapy group (20 minutes daily for five consecutive days) or a sham treatment group with an identical appearance. The primary efficacy endpoint is the remission rate of the Toronto Clinical Scoring System score one month after treatment (a decrease of ≥1 point). Secondary endpoints include short-term efficacy, pain visual analog scale scores, quality of life scores, and safety indicators. The study hypothesizes that shortwave therapy can significantly improve neurological symptoms, with an expected remission rate of 65% in the treatment group and 20% in the control group, with the superiority margin set at 20%. This study will provide high-quality evidence-based medical evidence for the use of shortwave therapy in diabetic peripheral neuropathy.
The 2 groups in the trial
- Placebo treatment groupSham treatment, for comparison
Using devices that are completely identical in appearance, the treatment process, screen display, and sounds are the same as the active group, but the devices are specially modified and do not emit electromagnetic energy. To ensure the success of blinding, the skin temperature of the treatment area will be measured before and after treatment, but the specific values will not be disclosed to the subjects.
- Shortwave therapy groupTreatment being tested
Using the CJ270-I model shortwave therapy instrument from Nanjing Congjing Biological Machinery Co., Ltd. Patients took a sitting position, placed both lower limbs into the therapy instrument, adjusted the power to 250W, frequency to 27.12MHz, once daily, 20 minutes each time, for 5 consecutive days.
Treatment: Short-Wave Diathermy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Shortwave Intervention for Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial(SIDPN)
- Plain-language title
- Shortwave therapy compared with sham treatment for nerve damage from diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07625007, who can take part
- Record updated
- 18 June 2026